L Macchi

Summary

Affiliation: CHU de Poitiers
Country: France

Publications

  1. ncbi Comparison of reticulated platelet count and mean platelet volume determination in the evaluation of bone marrow recovery after aplastic chemotherapy
    I Macchi
    Laboratoire d Hématologie et maladies du sang, CHU de La Miletrie, Poitiers, France
    Eur J Haematol 69:152-7. 2002
  2. ncbi Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate
    L Macchi
    Laboratoire d Hématologie et des maladies du sang, Hopital La Miletrie, 86 000, Poitiers, France
    Thromb Res 107:45-9. 2002
  3. ncbi Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms
    Laurent Macchi
    Laboratoire d Hématologie et des maladies du sang, CHU de Poitiers Hôpital La Miletrie, Poitiers, France
    J Am Coll Cardiol 42:1115-9. 2003
  4. ncbi Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance
    L Macchi
    Laboratoire d Hématologie et des maladies du sang, CHU de Poitiers, Hopital La Miletrie, 86 021 Poitiers, France
    Curr Pharm Des 12:251-8. 2006
  5. ncbi Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease
    L Christiaens
    département médico chirurgical de cardiologie, Hopital La Miletrie, 86021 Poitiers, France
    Thromb Res 108:115-9. 2002
  6. ncbi [Platelet polymorphism and coronary artery disease]
    L Christiaens
    département médico chirurgical de cardiologie, CHU Poitiers, 86021 Poitiers
    Arch Mal Coeur Vaiss 95:173-8. 2002
  7. ncbi [Aspirin resistance 2003: a review of the literature]
    L Christiaens
    département médico chirurgical de cardiologie, Pr Allal, CHU hôpital la Milétrie, Poitiers
    Arch Mal Coeur Vaiss 97:320-6. 2004
  8. ncbi Melagatran prevents tissue factor expression in human platelet-monocyte heterotypic complexes
    A Belliard
    Inserm U927, Poitiers, F 86021, France
    Cell Mol Biol (Noisy-le-grand) 54:OL1077-82. 2008
  9. ncbi Monitoring of the antiplatelet drugs effect in patients with coronary artery disease: what is the real clinical impact?
    Luc Christiaens
    département médico chirurgical de cardiologie, Centre Hospitalo Universitaire de Poitiers, hôpital de la Milétrie, Poitiers, France
    Curr Vasc Pharmacol 5:293-301. 2007
  10. ncbi Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study
    Luc Christiaens
    CHU Poitiers, Department of Cardiology, Research Clinical Center, Laboratory of Hematology, Poitiers, France
    Blood Coagul Fibrinolysis 19:235-9. 2008

Collaborators

Detail Information

Publications11

  1. ncbi Comparison of reticulated platelet count and mean platelet volume determination in the evaluation of bone marrow recovery after aplastic chemotherapy
    I Macchi
    Laboratoire d Hématologie et maladies du sang, CHU de La Miletrie, Poitiers, France
    Eur J Haematol 69:152-7. 2002
    ..We conclude that flow cytometric analysis of reticulated platelets is a sensitive and specific test for evaluating thrombopoiesis recovery during aplastic chemotherapy, and platelet transfusion should be reconsidered in these patients...
  2. ncbi Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate
    L Macchi
    Laboratoire d Hématologie et des maladies du sang, Hopital La Miletrie, 86 000, Poitiers, France
    Thromb Res 107:45-9. 2002
    ....
  3. ncbi Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms
    Laurent Macchi
    Laboratoire d Hématologie et des maladies du sang, CHU de Poitiers Hôpital La Miletrie, Poitiers, France
    J Am Coll Cardiol 42:1115-9. 2003
    ....
  4. ncbi Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance
    L Macchi
    Laboratoire d Hématologie et des maladies du sang, CHU de Poitiers, Hopital La Miletrie, 86 021 Poitiers, France
    Curr Pharm Des 12:251-8. 2006
    ..In conclusion, discovery of aspirin resistance in individuals might be important in order to devise better anti-platelet strategies and improve our ability to prevent acute thrombotic complication...
  5. ncbi Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease
    L Christiaens
    département médico chirurgical de cardiologie, Hopital La Miletrie, 86021 Poitiers, France
    Thromb Res 108:115-9. 2002
    ..Acetylsalicylic acid, or aspirin, is widely used in secondary prevention of coronary artery diseases, but the inhibition of platelet aggregation is not uniform in all individuals...
  6. ncbi [Platelet polymorphism and coronary artery disease]
    L Christiaens
    département médico chirurgical de cardiologie, CHU Poitiers, 86021 Poitiers
    Arch Mal Coeur Vaiss 95:173-8. 2002
    ..In addition, the study of these platelet polymorphisms gives a better insight into individual sensitivity to platelet antiaggregant therapy...
  7. ncbi [Aspirin resistance 2003: a review of the literature]
    L Christiaens
    département médico chirurgical de cardiologie, Pr Allal, CHU hôpital la Milétrie, Poitiers
    Arch Mal Coeur Vaiss 97:320-6. 2004
    ..This would support an individual adaptation of the anti-platelet therapy...
  8. ncbi Melagatran prevents tissue factor expression in human platelet-monocyte heterotypic complexes
    A Belliard
    Inserm U927, Poitiers, F 86021, France
    Cell Mol Biol (Noisy-le-grand) 54:OL1077-82. 2008
    ..Western blot analysis of PBMC extracts suggested that melagatran specifically targeted a (54kD) form of TF in monocytes. Although further investigation is warranted, these data suggest that melagatran decreases TF expression in PMHC...
  9. ncbi Monitoring of the antiplatelet drugs effect in patients with coronary artery disease: what is the real clinical impact?
    Luc Christiaens
    département médico chirurgical de cardiologie, Centre Hospitalo Universitaire de Poitiers, hôpital de la Milétrie, Poitiers, France
    Curr Vasc Pharmacol 5:293-301. 2007
    ..Therefore, it is not currently appropriate to test patients or to change therapy on the basis of such tests, other than in prospective and adequately powered clinical trials...
  10. ncbi Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study
    Luc Christiaens
    CHU Poitiers, Department of Cardiology, Research Clinical Center, Laboratory of Hematology, Poitiers, France
    Blood Coagul Fibrinolysis 19:235-9. 2008
    ..60). In this cohort of stable coronary artery disease, patients on aspirin dose of 160 mg per day, the aspirin-resistance status based on the PFA-100 results is not associated with a significant increase in major vascular clinical events...
  11. ncbi A rapid and specific whole blood HPA-1 phenotyping by flow cytometry using two commercialized monoclonal antibodies directed against GP IIIa and GP IIb-IIIa complexes
    Nathalie Sorel
    Laboratoire d Hématologie et des maladies du sang, CHU de Poitiers, Hopital La Miletrie, Poitiers 86021, France
    Br J Haematol 124:221-3. 2004
    ..These two monoclonal antibodies, coupled with flow cytometry represent a rapid and reliable tool for platelet HPA-1 typing to aid diagnosis...